CLE-100

Phase 2Small molecule

CClexio Biosciences Ltd.

CLE-100 is one of 52 small molecule programs targeting Major Depressive Disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Major Depressive DisorderActive, not recruiting

Major Depressive Disorder (MDD)Completed

Major Depressive DisorderPhase 2

Active, not recruiting

Major Depressive Disorder (MDD)Phase 2

Completed

Competition

Competitive Landscape

386 competitors in Major Depressive Disorder

#DrugCompanyPhaseTrials

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

12 2

Elavil

AstraZeneca

Phase 3

2 3

Daliresp

AstraZeneca

Phase 3

1 4

Crestor

AstraZeneca

Phase 3

1 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

5 6

Nuplazid

AACADIA Pharmaceuticals Inc.

Phase 3

4 7

Ketalar

Boehringer Ingelheim

Phase 3

3 8

Latuda

SSunovion Respiratory Development Inc.

Phase 3

3 9

Risperdal

WWim Janssens

Phase 3

2 10

Versed

CConrado Roberto Hoffmann Filho

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Major Depressive Disorder1 trial

A Study of CLE-100 (Oral Esketamine) in Addition to Standard Antidepressant Drug for Major Depressive Disorder - CLEO Study

Completed·CClexio Biosciences Ltd.·Phase 2·NCT04103892·146 enrolled

Major Depressive Disorder (MDD)1 trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Design, Phase 2 Study to Assess the Efficacy and Safety of CLE-100 as an Adjunctive Treatment for Major Depressive Disorder Patients With Inadequate Response to Standard Antidepressants

Completed·CClexio Biosciences Ltd.·Phase 2·NCT06340958·99 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for CLE-100. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — CLE-100 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for CLE-100. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Clexio Biosciences Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CClexio Biosciences Ltd.

CLE-100

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Major Depressive Disorder1 trial

Major Depressive Disorder (MDD)1 trial

References

Drug Info

Quick Facts

Related News